Cardio-oncology IPD-MA (ADAPT)
Research type
Research Study
Full title
Anthracycline-induced cardiotoxicity, high-sensitivity cardiac troponin, and cardiovascular risk: a meta-analysis of individual participant data from Cardiac CARE, PRADA, and PROACT
IRAS ID
366450
Contact name
Peter Henriksen
Contact email
Sponsor organisation
University of Edinburgh
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Anthracycline chemotherapy is essential in treating many common cancers but can lead to injuries in the heart, called cancer therapy induced heart damage. Previous clinical studies have explored the potential of using neurohormonal blockade drugs to protect patients from cancer therapy induced heart damage. However, these studies were small, lacked longer-term follow up, and mostly included low-risk patients for heart disease. Conducting large clinical studies in patients undergoing active cancer treatment would be ideal but has proven challenging, because the primary focus of care is effective cancer therapy and bespoke cross-disciplinary research network is required to support such studies. As cancer survival improves, cancer therapy related heart disease becomes more common and increasingly important. More data are needed to help clinicians understand the risk of heart disease in cancer survivors, identify biomarkers that indicate the risk, and select drugs that protect patients from heart injuries. In addition, a new risk score for cancer therapy related heart disease called the HFA-ICOS score has been developed, and will improve assessment of baseline risk for heart disease in cancer patients before the cancer treatment begins.
We propose a Meta-Analysis of Individual Participant Data (IPD-MA), to integrate data from three recent well-conducted clinical studies that have assessed common neurohormonal blockade drugs during anthracycline chemotherapy: PRADA, Cardiac CARE, and PROACT, and to collect and link long-term follow up data for patients in these studies. By doing so, we will create the largest patient-level dataset of neurohormonal blockade drug study during anthracycline chemotherapy, with longer follow-up than any individual clinical study in the field, and with a clear focus on late development of heart disease in cancer survivors for the first time.REC name
South West - Frenchay Research Ethics Committee
REC reference
26/SW/0005
Date of REC Opinion
19 Jan 2026
REC opinion
Favourable Opinion